본문 바로가기
KERD
논문KCI 등재

Results of Curative Radiation Therapy with or without Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer

송주영|김규식|정웅기|윤미선|남택근|김영철|나병식|안성자|Kyung-Ok Park
대한암학회 (Korean Cancer Association)|2005.10|Cancer Research and Treatment|제37권 제5호|pp. 268-272

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

RadiotherapyChemotherapyNon-smalcell lung cancer
주제분류의학일반

초록

Purpose: We retrospectively analyzed the patients who received curative radiotherapy for unresectable stage III NSCLC to investigate the impact of chemotherapy. Materials and Methods: From 1998 to 2001, the records of 224 patients who completed curative radiotherapy for NSCLC were reviewed. There were 210 males and 14 females, and their median age was 64 years (range 38 ∼83). 54 patients had stage IIIA disease and 170 patients had stage IIIB disease. Conventional radiotherapy was given and the radiation dose ranged from 50∼70 Gy with a median of 60 Gy, and chemotherapy was combined for 116 patients (52%). Results: The median survival, the 2-year, and 5-year actuarial survival rates of all 224 patients were 15 months, 30%, and 7%, respectively. The median survival of the patients with stage IIIA and IIIB disease were 21 months and 13 months, respectively (p=0.14). The median survival of patients who received chemoradiation was 18 months compared to 14 months for the patients who received RT alone (p=0.02). Among the chemoradiation group of patients, the median survival time of the patients who received 1 to 3 cycles of chemotherapy was 16 months and that for the patients who received more than 3 cycles was 22 months (p=0.07). We evaluated the effects of the timing of chemoradiation in 57 patients who received more than 3 cycles of chemotherapy. The median survival of the patients with the concurrent sequence was 25 months and that for the patients with the sequential chemotherapy was 19 months (p=0.81). Conclusions: For advanced stage III non-small cell lung cancer patients who completed the curative radiotherapy, the addition of chemotherapy improved the survival compared to the patients who received radiotherapy alone.

Abstract

Purpose: We retrospectively analyzed the patients who received curative radiotherapy for unresectable stage III NSCLC to investigate the impact of chemotherapy. Materials and Methods: From 1998 to 2001, the records of 224 patients who completed curative radiotherapy for NSCLC were reviewed. There were 210 males and 14females, and their median age was 64 years (range 38 ∼83). 54 patients had stage IIIA disease and 170 patients had stage IIIB disease. Conventional radiotherapy wasgiven and the radiation dose ranged from 50∼70 Gy with a median of 60 Gy, and chemotherapy was combined for 116 patients (52%). Results: The median survival, the 2-year, and 5-year actuarial survival rates of all 224 patients were 15 months, 30%, and 7%, respectively. The median survival of thepatients with stage IIIA and IIIB disease were 21 months and 13 months, respectively (p=0.14). The median survival of patients who received chemoradiation was 18months compared to 14 months for the patients who received RT alone (p=0.02). Among the chemoradiation group of patients, the median survival time of the patients who received 1 to 3 cycles of chemotherapy was 16 months and that for the patients who received more than 3 cycles was 22 months (p=0.07). We evaluated the effects of the timing of chemoradiation in 57 patients who received more than 3 cycles of chemotherapy. The median survival of the patients with the concurrent sequence was 25 months and that for the patients with the sequential chemotherapy was 19 months (p=0.81). Conclusions: For advanced stage III non-small cell lung cancer patients who completed the curative radiotherapy, the addition of chemotherapy improved thesurvival compared to the patients who received radiotherapy alone.

참고문헌 (17)

  1. "Multiinstitutional phase II trial of paclitaxel,carboplatin,a concurrent radiation therapy for locally advancednon-small-cell lung cancer", 16, pp.3316~22 (1998)
  2. "Improved survival in stage III NSCLC:Seven year follow-upof CALGB 8433 trial", 88, pp.1210~15 (1996)
  3. "Radiotherapy alone versus combined chemotherapyand radiotherapy in non-resectable non-small cell lungcancer:First analysis of a randomized trial of 353 patients", 83, pp.417~23 (1991)
  4. "Chemotherapyin non-small cell lung cancer:a meta-analysis usingupdated data on individual patients from 52 randomizedclinical trials", 311, pp.899~909 (1995)
  5. "Final results of phase III trial in regionallyadvanced unresectable non-small cell lung cancer: RadiationTherapy Oncology Group, Eastern Cooperative OncologyGroup, and Southwest Oncology", 117, pp.358~64 (2000)
  6. "Phase III study of concurrent versus sequentialthoracic radiotherapy in combination with mitomycin,vindesine,and cisplatin in unresectable stage III non-small-cell lungcancer", 17, pp.2692~99 (1999)
  7. "Phase III comparison of sequential vs concurrent chemoradiationfor patients with unresected stage III non-small celllung cancer (NSCLC) Report of Radiation Therapy OncologyGroup (RTOG) 9410.", 29, pp.93~ (2000)
  8. "Optimizing chemoradiation therapy approaches tounresectable stage III non-small cell lung cancer", 13, pp.110~5 (2001)
  9. "Randomized phase II chemotherapy and radiotherapy trialfor patients with locally advanced inoperable non-small-celllung cancer:long-term follow- up of RTOG 92-04", 53, pp.548~57 (2002)
  10. "Current strategies for radiation therapy in nonsmallcell lung cancer", 112, pp.209~13 (1997)
  11. "Preliminary results of a phase II study of weeklypaclitaxel (PTX) and carboplatin (CBDCA) administeredconcurrently with thoracic radiation therapy (TRT) followed byconsolidation chemotherapy with PTX", CBDCA for stage IIIunresectable non-small-cell lung cancer (NSCLC, 2004, pp.27, 603~10
  12. "Consolidation docetaxel after concurrent chemoradiotherpyin stage IIIB non-small- cell lung cancer:phaseII Southwest Oncology Group Study S9504", 21, pp.2004~10 (2003)
  13. "Toxicity and outcome results of RTOG 9311:aphase I-II dose escalation study using three-dimensionalconformal radiotherapy in patients with inoperable non-smallcelllung carcinoma", 61, pp.318~28 (2005)
  14. "Improved local control with higher dosesof radiation in large-volume stage III non-small-cell lungcancer", 60, pp.741~7 (2004)
  15. "Induction chemotherapy with carboplatin", paclitaxel followed by surgery or standard radiotherapy andconcurrent daily low-dose cisplatin for locally advanced nonsmallcell lung cancer (NSCLC)., 2003, pp.26, 265~9
  16. "Neoadjuvant concurrent radiochemotherapy inlocally advanced (IIIA-IIIB) non-small-cell lung cancer: longtermresults according to downstagin", 15, pp.389~98 (2004)
  17. "Concurrent cisplatin", etoposide plus chestradiotherapy followed by surgery for stage IIIA(N2) and IIIBnon-small-cell lung cancer: mature results of SouthwestOncology Group phase II study 8805., 1995, pp.13, 1880~92

관련 논문AI추천

Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer강진형, 김연실, 김영균, 박재길, 안명임, 왕영필, 유이령, 윤세철, 이동수, 이상남, 장홍석, 최병옥, 한대희대한암학회 · Cancer Research and Treatment2011 · 제43권 제1호Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer김보경, 노재명, 박근칠, 박효정, 선종무, 안명주, 안용찬, 안진석, 오동렬, 이언주, 이혜빈, 표홍렬대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy김보경, 김진만, 김진성, 노재명, 박효정, 신정숙, 안용찬, 오동률, 이언주, 주상규, 표홍렬, 홍채선대한암학회 · Cancer Research and Treatment2016 · 제48권 제1호Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients김동완, 김영환, 김태민, 김학재, 우홍균, 이세훈, 이주호, 허대석대한암학회 · Cancer Research and Treatment2012 · 제44권 제4호High Dose Involved Field Radiation Therapy as Salvage for Loco-Regional Recurrence of Non-Small Cell Lung Cancer김진국, 남희림, 박근칠, 박희철, 배선현, 심영목, 안명주, 안용찬, 안진석, 표홍렬, Kwhanmien Kim연세대학교의과대학 · Yonsei Medical Journal2012 · 제53권 제6호Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience김진국, 김홍관, 노재명, 박근칠, 박효정, 선종무, 심영목, 안명주, 안용찬, 안진석, 오동률, 조재일, 최용수, 표홍렬대한암학회 · Cancer Research and Treatment2017 · 제49권 제4호

이 간행물의 다른 논문 (9건)

Epstein-Barr Virus in Human Malignancy: A Special Reference to Epstein-Barr Virus Associated Gastric Carcinoma김우호, Mee Soo Chungpp. 257-267Treatment Outcomes of Three-Dimensional Conformal Radiotherapy for Stage III N on-Small Cell Lung CancerSun-Young Kim, 여승구, Moon-June Cho, Seung-Pyung Lim, Ki-Hwan Kim, Jun-Sang Kimpp. 273-278Oxaliplatin with Biweekly Low Dose Leucovorin and Bolus and Continuous Infusion of 5-fluorouracil (Modified FOLFOX 4) as a Salvage Therapy for Patients w ith Advanced Gastric CancerDong-Mee Lee, 김효진, 김성현, 김재석, 권혁찬, 서성환, Ji-Hoon Jo, Young-Rak Cho, Bong-Gun Seopp. 279-283Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal CancerYoung Ook Eum, Seong Woo Lim, Kyung Suck Cheoi, 한혜숙, Byung Chul Kim, 김승택, 이기형, Yoon Mi Shinpp. 284-289Comparison of WHO and RECIST Criteria for Response in Metastatic Colorectal CarcinomaJin-Woo Kim, 이강홍, 최정혜, Young-Yeul Lee, In-Soon Kim, Myung-Ju Ahn, Hyan-Chul Rhimpp. 290-293
원문 보기